< Back to previous page

Project

Peptide based CXCR4 targeting for PET imaging and radionuclide therapy

Increased understanding of the pivotal role of CXCR4 in tumor biology has
resulted in the development of radiopharmaceuticals that can provide
sensitive detection of CXCR4 expression and allow patient selection for
CXCR4-targeted therapies. [68Ga]Pentixafor is the only CXCR4-targeted
imaging agent that has found broad clinical applicability so far. However, due
to the low production capacity, implementation of [68Ga]Pentixafor in clinical
practice is still limited. Further, results with the therapeutic companion
radiopharmaceutical [177Lu]Pentixather are promising, but there is still room
for improvement regarding pharmacokinetics and dosimetry profile. Moreover,
an CXCR4-targeted radiopharmaceutical labeled with an α-emitter might
present a breakthrough in therapy of various CXCR4 expressing tumors such
as multiple myeloma. Therefore, the aim of this study is to develop innovative
CXCR4 radiopharmaceuticals, both for diagnostic and therapeutic purposes,
starting from new vector molecules that have not been explored yet for
nuclear medicine applications.

Date:1 Jan 2021 →  Today
Keywords:nuclear medicine applications., imaging based radiotherapy, small animal imaging, tracer development
Disciplines:Diagnostic radiology, Cancer therapy